Dr. Bates has been invited to present her work on long-term outcomes in survivors of prematurity at the Pediatric Academic Societies meeting in Philadelphia on May 4th, 2020. She will share the platform with renowned physician-scientists including Anne-Monique Nuyt, Kara Goss, Philip Levy, Adam Lewandoski, and Patrick McNamara. Together, this group is dedicated to defining how prematurity, and the interventions we use to care for these tiny babies, impact cardiovascular development and increase the long-term risk of cardiovascular disease.
Prematurity is a historically recent phenomenon and these children only began surviving prematurity on a large scale in the early 1990s when surfactant became available. We still have so much to learn about how these children grow and develop into adulthood and Dr. Bates is excited to share some of her findings with the pediatrics community!
This award from the American Physiological Society is the highest honor given to an early career scientist in respiratory physiology. According to the APS website:
The Giles F. Filley Memorial Award for Excellence in Respiratory Physiology and Medicinerecognizes excellence in respiratory physiology and medicine. The award is given to an investigator who holds an academic rank no higher than assistant professor. The award is presented annually to an individual demonstrating outstanding promise based on his/her research program in respiratory physiology and medicine.
Giles Filley was drawn to respiratory medicine after contracting tuberculosis. His own health struggles, and his observations at the Trudeau Sanitarium where he received treatment, inspired him to conduct research to improve patients’ lives. Dr. Filley is most remembered for his work in acid-base balance and his invention of a volume-controlled ventilator that made its way into clinical practice.
Dr. Filley’s motivation to do work that helps people continues to be an inspiration for our own work!
Thank you to all of the outstanding women in the lab, and women that we collaborate with, who contribute every day to our mission to develop new strategies to prevent and treat disease, by completely considering the contribution of genetics, environmental factors, and pathophysiological modifiers.
We are pleased that the work of two outstanding undergraduates has been published in the Journal of Visualized Experiments. McKayla Seymour (Class of 2018) and Elizabeth Pritchard (Class of 2019) spearheaded the effort to publish our method that uses volumetric capnography and plethysmography to measure what we call the “lung structure-function relationship“. The paper contains video instructions of the method, step-by-step written instructions, and information about its validation. We are so grateful for these talented physiologists’ efforts to share our method with the scientific community and hope it is of use to other scientists and clinicians interested in lung disease.
We are pleased to announce that Hannah Welper has joined the lab this semester as a master’s thesis student! Hannah has already worked to establish expertise in hypoxia and multiple myeloma and will be looking at factors that impact the tumor microenvironment.
Drs. Bates and Tomasson, in collaboration with other investigators from the University of Iowa multiple myeloma group, have been awarded a one year grant to study the factors that drive the transition from pre-malignancy to malignancy in multiple myeloma. This award extends the lab’s current history of work in myeloma treatment and prevention, will provide the framework for studying the interaction between genetic mutations and environmental stressors.
We look forward to this exciting opportunity to continue our work!!!!
We are pleased to announce the publication of our most recent paper titled “Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma,” which is free to view here.
Screening and prevention strategies have been used successfully in some solid tumor cancers, including breast, colon, and prostate. Multiple Myeloma is essentially always preceded by a non-malignant precursor stage called Monoclonal Gammopathy of Undetermined Significance (MGUS). We believe that if we could identify ways to prevent the transition from pre-malignant MGUS to myeloma, we could reduce the personal, societal and economic burden of this devastating blood cancer. In our paper, we review some possible prevention strategies. We also provide the first data on the incidence of sleep-disordered breathing and daytime sleepiness in myeloma patients, and comprehensively detail the multi-million dollar cost of treating this disease.
Thank you to all the lab members and collaborators who contributed to this effort. We hope this paper will be helpful to the scientific and patient community, and to find others who also believe that prevention is the best treatment.